Literature DB >> 9684701

Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin.

C Hottelart1, J M Achard, P Moriniere, F Zoghbi, J Dieval, A Fournier.   

Abstract

Aldosterone suppression and subsequent hyperkalemia are well described reversible side effects of prolonged treatment with heparin. This study was designed to examine whether the discontinuous use of heparin three times a week to prevent thrombosis formation during hemodialysis sessions could also induce hypoaldosteronism and might contribute to increased predialysis kalemia in hemodialysis patients. Two different heparinization regimens were prospectively compared in a crossover study of 11 chronic hemodialysis patients. During 2 consecutive weeks, the patients were dialyzed each week with either their usual doses of unfractionated heparin (UH) (6,160 IU +/- 1,350 IU) or low molecular weight heparin (LMWH) (15 anti-Xa activity [aXa] U/kg + 5 aXa U/kg/h). In all but 2 patients, the predialysis level of plasma K+ was higher with UH than with LMWH, and the mean value was higher (5.66+/-0.83 versus 5.15+/-0.68 mM, p = 0.01) while no differences in the predialysis plasma concentrations of creatinine, phosphate, urea, and bicarbonate were observed, excluding the potential role of differences in diet and dialysis efficacy in explaining the higher plasma K+ concentration with UH. The mean plasma aldosterone to plasma renin activity (pRA) ratio was higher with LMWH than with UH (149.54+/-123.1 versus 111.91+/-86.22 pg/ng/ h, p < 0.05). Individual plasma aldosterone values were found to be correlated to pRAs both during the UH period and the LMWH period, and the slope of the positive linear relation between plasma aldosterone and pRA was lower during the UH treatment period (63 versus 105 pg/ng/h). Finally, a negative linear correlation was found between the differences in individual predialysis plasma K+ observed during the 2 protocols and the differences in the corresponding plasma aldosterone levels, suggesting a link between the higher kalemia and the lower aldosterone responsiveness to angiotensin with unfractionated heparin. Although it cannot be concluded whether or not LMWH inhibits aldosterone synthesis, should LMWH decrease aldosterone production, this side effect is 33% less marked than that of UH so that the predialysis plasma K+ levels are 10% lower. This property makes LMWH use preferable to that of UH in patients with elevated predialysis kalemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684701     DOI: 10.1046/j.1525-1594.1998.06204.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  9 in total

Review 1.  Unfractionated heparin for hemodialysis: still the best option.

Authors:  Robert E Cronin; Robert F Reilly
Journal:  Semin Dial       Date:  2010 Sep-Oct       Impact factor: 3.455

2.  Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.

Authors:  Giuseppe Gheno; Leonardo Cinetto; Carmelo Savarino; Sandro Vellar; Maurizio Carraro; Massimo Randon
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

Review 3.  Anticoagulation in CKD and ESRD.

Authors:  Kelvin Cheuk-Wai Leung; Jennifer Marie MacRae
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

Review 4.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

5.  A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study.

Authors:  Oliver Dorsch; Detlef H Krieter; Horst-Dieter Lemke; Stefan Fischer; Nima Melzer; Christian Sieder; Peter Bramlage; Job Harenberg
Journal:  BMC Nephrol       Date:  2012-06-28       Impact factor: 2.388

Review 6.  Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis.

Authors:  Ghanshyam Palamaner Subash Shantha; Anita Ashok Kumar; Mansha Sethi; Rohit C Khanna; Samir Bipin Pancholy
Journal:  PeerJ       Date:  2015-03-10       Impact factor: 2.984

7.  The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial.

Authors:  Davina J Tai; Kelvin Leung; Pietro Ravani; Robert R Quinn; Nairne Scott-Douglas; Jennifer M MacRae
Journal:  BMC Nephrol       Date:  2015-08-25       Impact factor: 2.388

8.  Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.

Authors:  Nima Melzer; Peter Bramlage; Hans-Christoph Michaelis
Journal:  BMC Res Notes       Date:  2014-12-06

9.  Heparin-Induced Hyperkalemia in a Dog Receiving Continuous Renal Replacement Treatment.

Authors:  B Geesaman; J Bach; K Monaghan
Journal:  J Vet Intern Med       Date:  2015-10-08       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.